01 January 2002
CD44 in the immunodiagnostics of colorectal cancer
Maria Sobaniec-Łotowska , Józef Pogumirski , Mariola Sulkowska , Małgorzata Barwijuk-Machała , Bogdan Zalewski , Waldemar Famulski , Teresa Woińska-RojeckaCase Rep Clin Pract Rev 2002; 3(3):200-203 :: ID: 474517
Abstract
Poland belongs to the group of countries characterized by a low incidence of colorectal cancer. However, this incidence shows a steady increasing tendency. Very low rate of success in treating large intestine cancer in our
country is mainly caused by its late diagnosis. One condition to change this situation is introduction of new methods directed at very early diagnosis apart from application of widespread screening methods: examinations for
occult blood and colonoscopy as a prophylaxis. One of the suggested methods for the diagnosis of colon cancer apart from the so far widely used methods (for example per rectum examination, tests for occult blood, tests for CEA — antigen in the serum) is the examination of the immunoreactivity of exfoliated colon cells from the feces for the presence of CD44 antigen. In this
paper we present the role of intermembranous glycoprotein CD44 which is an adhesive molecule and antigen used in the early immunodiagnosis of large intestine cancer. The expressions of CD44 and PCNA protein dependent
on the cell life cycle have been compared with a suggestion that CD44 overexpression in colon cancers is asynchronically associated with the replications of the cell. In the publication we focused on the standard
form of CD44 glycoprotein coded on the short arm of human chromosome 11 of 90 kDa molecular weight and its most common isoforms (CDv6, CDv10) observed during the course of this cancer. After the tumor resection
CD44v6 and CD44v10 levels were found to have decreased significantly. It should be emphasized that finding the above markers in the stool is a completely non-invasive method while being very helpful in the early immunodiagnosis of colorectal cancer. This study was done within Research Programme Nr 3P05B 07922, financed by KBN.
Keywords: glycoprotein CD44, colorectal cancer, immunodiagnostics
516
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






